secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001789769-23-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio resumes Phase 1 trial of ITIL-306; initial data expected in 2023
---------------------------------------------------------------------------

- Phase 1 trial of ITIL-306 (CoStAR-TIL) for NSCLC, ovarian, and renal cancer re-opened after voluntary pause.
- Initial safety, translational, and efficacy data from dose escalation cohorts expected in 2023.
- Resumption follows implementation of additional quality safeguards in manufacturing process.
- Company expects cash runway into 2025, excluding potential monetization of Tarzana manufacturing site.
- Recent reprioritization of clinical programs and corporate restructuring completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000004/0001789769-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000004/til-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001789769-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer